Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
melanoma
|
|
0.700 |
GeneticVariation
|
CLINVAR |
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
|
24265155 |
2014 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
COWDEN SYNDROME 5
|
|
0.700 |
GeneticVariation
|
UNIPROT |
Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.
|
23246288 |
2013 |
ovarian neoplasm
|
|
0.700 |
CausalMutation
|
CLINVAR |
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
|
22271473 |
2012 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
|
22162589 |
2012 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials.
|
22162582 |
2012 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
Colorectal Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
|
20619739 |
2010 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |
Mammary Neoplasms
|
|
0.700 |
CausalMutation
|
CLINVAR |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
|
20453058 |
2010 |